PhoreMost

PhoreMost has developed a next-generation phenotypic screening platform called SITESEEKER®, which can identify the best new targets for future treatments and, crucially, how to drug them. This has the potential to significantly increase the diversity of novel therapies for cancer and other unmet diseases. SITESEEKER is based on the company's core proprietary "Protein Interference" technology, systematically uncovering druggable sites hidden across the entire human genome and linking them directly to useful therapeutic functions within living cells. By using this platform, PhoreMost is establishing a new drug discovery initiative aimed at addressing a range of unmet diseases.